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Human Cancer Biology
MicroRNA-494 Downregulates KIT and Inhibits
Gastrointestinal Stromal Tumor Cell Proliferation
Won Kyu Kim1,2, Misun Park1,2, Young-Kook Kim4, Kwon Tae You4, Han-Kwang Yang5,
Jae Myun Lee1,3, and Hoguen Kim1,2
Abstract
Purpose: Gain-of-function mutations and KIT overexpression are well-known tumorigenesis mechan-
isms in gastrointestinal stromal tumors (GIST). This study aimed to discover microRNAs (miRNA) that
target KIT and reveal the relationship between the discovered miRNAs and KIT expression in GISTs.
Experimental Design: Fresh-frozen GISTs from 31 patients were used to confirm the relationship
between miR-494 and KIT expression using quantitative reverse transcription-PCR to assess miR-494
expression levels and Western blotting to assess KIT protein expression levels. A luciferase assay was
conducted for the target evaluation. The functional effects of miR-494 on GIST882 cells (GIST cell line with
activating KIT mutation) were validated by a cell proliferation assay and fluoresce-activated cell sorting
analysis.
Results:An inverse relationship was found between the expression levels of miR-494 and KIT in GISTs
(r ¼ 0.490, P ¼ 0.005). The direct targeting of KIT by miR-494 was shown by the reduction in KIT
expression after miR-494 overexpression and the increase in KIT expression after inhibiting endogenous
miR-494 expression. We showed that miR-494 regulates KIT by binding two different seed match sites.
Induced miR-494 overexpression in GIST882 reduced the expression of downstream molecules in KIT
signaling transduction pathways, including phospho-AKT and phospho-STAT3. Finally, miR-494 over-
expression provoked apoptosis and inhibited GIST cell growth, which were accompanied by changes in
G1 and S phase content.
Conclusion: Our findings indicate that miR-494 is a negative regulator of KIT in GISTs and over-
expressing miR-494 in GISTs may be a promising approach to GIST treatment. Clin Cancer Res; 17(24);
7584–94. 2011 AACR.
Introduction
Themolecular genetics of gastrointestinal stromal tumors
(GIST)areamongthebestunderstoodofhumantumors(1).
Two oncogenes of the receptor tyrosine kinase family,
KIT and PDGFRA, have gain-of-function mutations in
approximately 70% and 15% of GISTs, respectively (2, 3).
Mutationsof these2 genes cause sustained activation, result-
ing in constant stimulation of the downstream signaling
pathways of KIT andplatelet-derived growth factor receptor,
alpha polypeptide (4, 5). Of these genes, KIT activation is
especially crucial to the development and progression of
GISTs (3). The downstream molecular pathways involved
in GIST tumorigenesis after KIT mutation include PI3
kinase-AKT, Src family kinase, Ras-ERK, and JAK-STAT
(6). Activation of these molecular pathways after KIT
activation results in GIST tumorigenesis through cell pro-
liferationactivationandapoptotic signal inhibition(4,6,7).
The progression of GIST is successfully blocked by ima-
tinib, which suppresses KIT by competitively binding its
ATP-binding pocket, inhibiting KIT activation, and block-
ing the activation of the downstream MAP kinase and PI3
kinase-AKT pathways (7, 8). However, the development of
imatinib resistance during imatinib treatment reduces the
inhibitory effects of imatinib. Therefore, more diverse
approaches to inhibit-activated KIT via posttranscriptional
and posttranslational mechanisms are required for GISTs
with KIT activation (9–11).
KIT overexpression has been reported as a characteristic
feature of GISTs, and the presence of KITmutations usually
leads to strong KIT expression (12, 13). Although KIT
mutations are present in approximately 70% of GISTs, KIT
overexpression is observed in more than 90% of GISTs,
suggesting that a complementarymechanismparticipates in
KIT overexpression (2, 14). Dysregulation of microRNAs
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(miRNA) is a possible mechanism, as miRNAs play impor-
tant roles in regulating gene expression in cancers (15, 16).
In erythroleukemic cells, miR-221/miR-222 are presently
reported to target KIT (17). In GISTs, no miRNAs targeting
KIT have been identified. We previously compared KIT
expression and miRNA expression profiles in GISTs and
identified 5 possible candidate miRNAs for which their
expression is inversely related to KIT expression (13). In this
study,weproposedthatmiR-494regulatesKITexpressionby
showing that (i) miR-494 expression is inversely correlated
with KIT expression inGIST tissues, (ii) exogenousmiR-494
induces KIT downregulation, and (iii) inhibition of endog-
enous miR-494 increases KIT expression. We also showed
that miR-494 represses the proliferation of a GIST cell line
with a KIT-activating mutation (GIST882; ref. 7). Taken
together, our results suggest that miR-494 is involved in
GIST tumorigenesis via regulating KIT expression.
Materials and Methods
Cell lines and culture
The GIST882 cell line with an activating KIT mutation
(exon 13, K642E) was a generous gift from Dr. Jonathan
Fletcher, Harvard University, Cambridge, MA. SNU216,
SNU638, SNU1, NCI-N87, DLD-1, and HeLa cells were
purchased from the Korean Cell Line Bank (Cancer
Research Institute, Seoul, Korea). Cell culture images were
taken with an IX71 camera (Olympus).
Patient and tissue samples
The 31 GISTs included in this study were identified in the
Department of Pathology at Yonsei University Medical
Center between August 1997 and June 2006 for molecular
marker studies. Authorization to use these tissues for
research purposes was obtained from the Institutional
Review Board of Yonsei Medical Center. Some of the fresh
specimens were obtained from the Liver Cancer Specimen
Bank of the National Research Resource Bank Program of
the Korea Science and Engineering Foundation of the Min-
istry of Science and Technology. Among the 31 GISTs, 17
samples had previously been used for miRNA profiling and
proteomic analyses (12, 13, 18, 19). Conventional patho-
logic parameters including anatomic site, risk, and tumor
size were examined prospectively without prior knowledge
of themolecular data (Table 1). TheGISTswere divided into
4 groups based on tumor risk according to the criteria of
Fletcher and colleagues (1, 20).
RNA preparation and TaqMan miRNA assay
Total RNA was extracted from frozen tissues using TRI-
ZOL (Life Technology). The expression levels of miRNA
were quantified by the TaqMan miRNA assay (Applied
Biosystems) and analyzed with an Applied Biosystems
7300 Real-Time PCR system. The assay ID was 002365 for
miR-494 and 001093 for RNU6B, which was used to
normalize miR-494 levels in the samples. Data analysis was
conducted using both quantity values for miR-494 from
GIST tissues and Ct values (2
DDCT method; ref. 21) to
measure the induced expression of miR-494 in HeLa and
GIST882 cells. All assays were carried out in triplicate.
Quantitative reverse transcription-PCR
The quantitative reverse transcription-PCR (qRT-PCR)
primer sequences for KIT (PrimerBank ID; 4557695a2) and
glyceraldehydes-3-phosphate dehydrogenase (GAPDH;Pri-
merBank ID; 2282013a2) were obtained from the Primer-
Bankdatabase (http://pga.mgh.harvard.edu/primerbank/).
The reaction was carried out in a final volume of 20 mL with
Premix Ex Taq (TAKARA) according to the manufacturer’s
instructions. All reactions were run on an ABI Prism 7300
Real-Time PCR system in triplicate. The analysis of the
results was conducted with quantity values using 7300
system SDS software (Applied Biosystems), and GAPDH
was used for normalization. KIT mRNA levels were pre-
sented as the relative levels compared with the KIT mRNA
levels in negative control samples in all figures.
miRNA mimics and transfection
Appropriate miRIDIAN miRNA mimics (nontargeting
miRNA, miR-221, miR-222, and miR-494 miRNAs, and an
miR-494 inhibitor; Thermo Scientific) were used in this
study. All transfection experiments were carried out using
Lipofectamine 2000 (Invitrogen). On the third day after
transfection, all cells were harvested and managed for
further Western blot analysis.
Western blots
Whole lysates from samples were prepared using passive
lysis buffer (Promega). Primary antibodies used were
against GAPDH (Trevigen), KIT, STAT3, ERK, phospho-ERK
Translational Relevance
Gastrointestinal stromal tumors (GIST) have changed
from being poorly defined to well-recognized tumors.
Mutations of KIT and platelet-derived growth factor
receptor, alpha polypeptide are major factors causing
the development of GISTs. Of those genes, activating
mutations of KIT are particularly crucial to the develop-
ment and progression of GISTs. Imatinib (STI571),
which blocks KIT activation, has been successfully
applied to treat patients with GISTs. However, imati-
nib-resistant mutations are frequently found in patients
with GISTs during treatment. Therefore, the develop-
ment of alternative therapeutic tools is required. One of
the alternatives is microRNA (miRNA)-based therapy.
We previously found 5miRNAs, the expression of which
was inversely related to KIT expression in GISTs. Of
these 5 miRNAs, we verified an inverse relationship
between miR-494 and KIT expression in 31 GISTs. We
also showed that miR-494 downregulates KIT, and miR-
494 overexpression inhibits GIST cell growth. Therefore,
KIT inactivation through miR-494 might be another
promising approach for GIST treatment.
MiR-494 Downregulates KIT
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(Santa Cruz Biotechnology), phospho-KIT (Invitrogen),
AKT, phospho-AKT, and phospho-STAT3 (Cell Signaling).
The Western blot images were analyzed with a LAS-4000
Mini camera (Fujifilm).
Luciferase reporter assay
We designed a reporter assay by generating a vector
(named N) with the coding sequences for Renilla luciferase
and the entire 30-untranslated region (UTR) sequences of
KIT that were obtained from cDNAs of GIST882 cells. The
30-UTR sequences (NCBI reference sequence; NM_000222)
obtained from GIST882 by PCR amplification were cloned
downstream of the SV40 enhancer and the early promoter-
driven Renilla luciferase cassette in a pRL3 vector (Pro-
mega). The N vector was then used to generate 2 mutant
constructs by mutating complementary seed sequences in
the miR-494, miR-221, or miR-222–binding region. Using
site-directed mutagenesis of the KIT 30-UTR sequence in the
Nvector, both theMvector formiR-494,whichhad changes
fromnucleotides 1899 to 1902 (GTTT!CCGG), and theO
vector for miR-221/miR-222, which had changes from
nucleotides 1961 to 1964 (GTAG! CAGA), were generat-
ed. We also constructed 3 additional vectors from the M
vector for the identification of additionalmiR-494–binding
sites. Additional mutagenesis (GTTT ! CCGG) of the
potential miR-494–binding sites was conducted at posi-
tions 1,222 to 1,228 (TGTTTCT), 1,758 to 1,765
(GTGTTTCT), and 1,918 to 1,923 (ATGTTT). The vectors
were named Ma, Mb, and Mc, respectively. The pGL3
luciferase reporter vector was used as a control vector for
the dual luciferase assay (Promega). The oligonucleotide
sequences used for vector construction are listed in Supple-
mentary Table S1. Every dual luciferase assaywas carriedout
by cotransfecting a control vector with theN,M,O,Ma,Mb,
or Mc vector. All miRNA mimics were transfected at a
concentration of 5 nmol/L. Two days after transfection, the
luciferase activity was measured according to the manufac-
turer’s instructions.
Cell proliferation assay
The GIST882 cells and DLD-1 cells were transfected with
50 nmol/L nontargeting miRNA ormiR-494. Themorphol-
ogy of the 2 cells was examined daily and the cells were
manually counted. The DLD-1 cells were washed with PBS
and SCF containing media (10 ng/mL) with 2% FBS added
to the cells after 48 hours of transfection. The numbers of
the cells were counted 2 days after SCF stimulation. Every
sample was duplicated, and the mean result was used for
further analyses. A cell proliferation assaywas independent-
ly conducted in triplicate.
Cell-cycle analysis
GIST882 cells were transfected with 50 nmol/L nontar-
getingmiRNA ormiR-494 in 60-mmdishes. On the 4th day
after transfection, cells of each sample were stained in a
solution of PBS, propidium iodine (PI; Abcam), and RNase
A. All samples were analyzed by a FACS Calibur (BD
Biosciences). We also analyzed apoptosis after miR-494
transfection in GIST882. For Annexin V staining, GIST882
cells were harvested on the 6th day after transfection of 50
nmol/L nontargeting miRNA or miR-494, and then a Fluo-
rescein isothiocyanate Annexin V Apoptosis Detection Kit l
(BD biosciences) was used according to the manufacturer’s
instructions. All samples were analyzed by a FACS Calibur.
Each experiment was conducted in triplicate.
Results
Identifying miR-494 as a negative regulator of KIT
Our previous microarray data were used to evaluate the
effect of 5 candidate miRNAs on KIT expression. Five
candidate miRNAs were chosen because their expression
levels had a statistically meaningful relationship with KIT
expression in GISTs (13). To confirm the microarray data,
25 nmol/L of each of the 5 candidate miRNAs (miR-9, miR-
142-5p, miR-370, miR-494, andmiR-510) were transfected
into KIT-overexpressing GIST882 cells. Western blot anal-
ysis of the transfected samples revealed that only miR-494
overexpression consistently reduced KIT protein expression
(Supplementary Fig. S1). We validated the inverse correla-
tion between miR-494 and KIT expression in GISTs by
conducting qRT-PCR to measure miR-494 expression and
Western blotting to assess KIT protein expression. For these
analyses, we used 31 fresh-frozen GIST samples consisting
of 25 GISTs with a KITmutation and 6 GISTs without a KIT
mutation (Table 1). The expression of miR-494 was ana-
lyzed using the mean values from 3 independent qRT-PCR
experiments for each sample. The expression of KIT and
miR-494 for each tissue was presented as a fold change (log
scale) relative to the mean value of KIT and miR-494
expression, respectively, to compare the expression levels
among the tumor samples (Fig. 1A and Supplementary Fig.
S2). We found an inverse relationship between expression
of KIT and miR-494 (Spearman’s correlation coefficient,
r ¼ 0.490, P ¼ .005).
After we validated the relationship between KIT and
miR-494 expression in GISTs, we compared the efficiency
of KIT downregulation of miR-494 with 2 previously
reported KIT targeting miRNAs, miR-221/miR-222 (17).
The ability of miR-494 to induce KIT downregulation was
confirmed by transfecting GIST882 cells with 25 nmol/L
nontargeting miRNA, miR-494, miR-221, or an miR-494
inhibitor. The nontargeting miRNA was used as a negative
control, whereas miR-221 served as a positive control for
comparisons with miR-494. The induction of miR-494
after transfection was determined by qRT-PCR. When we
transfected GIST882 cells with 25 nmol/L miR-494, miR-
494 expression was increased approximately 25-fold com-
pared with that in nontransfected cells (Supplementary
Fig. S3A). The results of Western blotting showed signif-
icant downregulation of KIT expression when the cells
were transfected with miR-494 or miR-221, with miR-494
having greater efficacy than miR-221. qRT-PCR analysis
revealed the same expression pattern as the Western blot
analysis, except for slightly increased KIT mRNA levels in
the cells transfected with an miR-494 inhibitor (Fig. 1B).
MiR-494 Downregulates KIT
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There were no remarkable differences in the efficacy of
miR-221 and miR-222 in downregulating KIT (data not
shown). Then, we measured miR-494 expression in 4
gastric cancer cell lines, GIST882 cells and HeLa cells to
determine why miR-494 inhibition did not affect KIT
expression in GIST882 cells. As expected, GIST882 cells
exhibited very low miR-494 expression (less than 10%
of that in the other cell lines; Supplementary Fig. S4).
These results indicate that KIT expression is regulated by
miR-494.
Identifying 2 seed match sites in the 30-UTR of KIT
Weconfirmed that KITmRNA is a direct target ofmiR-494
by identifying miR-494–binding sites in the 30-UTR of KIT.
Searching the Target Scan 3.0 database (http://www.targets-
can.org/) to find algorithm-based–binding sites ofmiR-494
in the 30-UTR of KIT mRNA, 1 binding site was predicted at
nucleotide positions 1,897 to 1,903 (site 3; Fig. 2A).We first
generated the N vector, which contained the coding
sequences for Renilla luciferase and the entire wild-type
30-UTR sequences of the KIT mRNA. Then, we conducted
a reporter assay in which 5 nmol/L nontargeting miRNA,
miR-494, miR-221, or miR-222 was transfected with the N,
O, or M into HeLa and SNU216 cells. Similar results were
obtained in both cell lines and the figure shows represen-
tative data from HeLa cells. To confirm the induced expres-
sion of exogenous miR-494, we extracted RNA from sepa-
rately collected small amounts of cells used for the DLR
assay. Compared with that of the negative control, an
approximate 10-fold increase in miR-494 expression was
observed in HeLa cells transfected with 5 nmol/L miR-494
(Supplementary Fig. S3B). The reporter assay revealed that
cells transfected with the N vector and miR-494 exhibited
approximately half of the luciferase activity compared with
cells transfected with the N vector and nontargetingmiRNA
and more severe decreases in luciferase activity than cells
transfected with miR-221 and miR-222. The results also
showed that the luciferase activity in cells transfected with
the O vector and miR-221 or miR-222 was fully recovered
comparedwith that in the negative control (cells transfected
with theN vector and nontargetingmiRNA), indicating that
miR-221 and miR-222 directly target KIT mRNA. However,
samples transfected with the M vector and miR-494 only
had slightly recovered luciferase activity comparedwith that
of the negative control (Fig. 2B). On the basis of this result,
wehypothesized that (i)miR-494maynot directly target the
30-UTR of KIT or (ii) additional miR-494–binding sites may
exist.
Wemanually searched for additional potentialmiR-494–
binding sites with Vector NTI software (Invitrogen; Fig. 2A).
The 30-UTR of KIT had 3 additional putative miR-494–
binding sites that harbor 6 to 7 seed match sequences with
miR-494. The putative miR-494–binding sites were
TGTTTC (site 1, nucleotide positions 1,222–1,227),
GTGTTTC (site 2, 1,758–1,764), and ATGTTT (site 4,
1,918–1,923; Fig. 3A). These findings led us to create 3
additional vectors, Ma, Mb, and Mc, which were derived
from the M vector by additional mutagenesis (GTTT !
CCGG) of the potential miR-494–binding sites. The report-
er assaywas conducted by transfecting theM,Ma,Mb, orMc
vector withmiR-494 into HeLa and SNU216 cells. Only the
cells transfected with Mb and miR-494 had fully recovered
luciferase activity compared with that in the negative con-
trol (Fig. 2C). Because the G (1753) of the GTGTTTCT
sequence (1,753–1,760) can hydrogen bond with U via a
wobble match, this site worked nearly and the same orig-
inal-binding site suggested by Target Scan 3.0. We also
found that only the Mb vector fully restored luciferase
activity in GIST882 cells when it was cotransfected with
miR-494 (Supplementary Fig. S5). On the basis of these
results we concluded that 2 different sites are important for
miR-494 to bind the 30-UTR of KIT.
Restoring KIT expression after miR-494 inhibition in
the cell lines with high miR-494 expression
We determined the ability of endogenous miR-494 to
bind to the 30-UTRof KIT by designing a reporter assay using
the N vector and an miR-494 inhibitor. Prior to this
Figure 1. KIT expression is inhibited by miR-494 overexpression. A, KIT
protein expression is inversely correlated with miR-494 expression.
Western blotting and qRT-PCR was used to quantify the expression of
KIT and miR-494, respectively. An inverse relationship between KIT
protein expression and miR-494 expression was evident (r ¼ 0.490,
P ¼ .005). B, changes in KIT protein expression after miR-494
transfection.GIST882 cellswere transfectedwith 25 nmol/L nontargeting
miRNA, miR-221, miR-494, or miR-494 inhibitor. KIT protein expression
was reduced to approximately 57% of negative control (nontargeting
miRNA transfection) levels aftermiR-494 transfection. qRT-PCR analysis
indicated that KIT mRNA levels decreased in cells transfected with
miR-494 and miR-221. N.C. denotes the negative control transfected
with nontargeting miRNA. % denotes the relative intensity of protein
expression.
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inhibition assay, we selected 3 cell lines (HeLa, SNU216,
and GIST882) based on their endogenous miR-494 expres-
sion levels. HeLa and SNU216 cells had relatively highmiR-
494 expression, but miR-494 expression was barely detect-
able in GIST882 cells. These 3 cell lines were each trans-
fected with the N vector and nontargeting miRNA (for
negative control) or with the N vector and an miR-494
inhibitor. The cells were harvested after 2 days, and theDLR
assay was carried out. SNU216 and HeLa cells transfected
with anmiR-494 inhibitor had approximately 2-fold higher
luciferase activities than their respective negative controls.
As expected, no changes in luciferase activity were observed
inGIST882 cells because these cells express very low levels of
miR-494 (Fig. 2D). These results indicate that KIT
Figure 2. Identiﬁcation of 2 binding
sites for miR-494 in the KIT 30-UTR.
A, schematic diagram of vector
constructs used in the reporter
assay. The N vector contained the
coding sequences for Renilla
luciferase and the entire 30-UTR
sequence of KIT. The M construct
included 4 mutated nucleotides
(GTTT! CCGG) from the
TargetScan3.0 expected binding
seed sequences for miR-494. The
Ma, Mb, and Mc constructs were
generated from the M construct by
substituting 4 nucleotides (every
GTTT ! CCGG) in putative miR-
494–binding sites. The O vector was
generated from N vector by
substituting site 5 (GTAG ! CAGA)
to conﬁrm that all constructs worked
properly by showing the proper
targeting of miR-221/miR-222 to the
KIT 30-UTR. B, reporter assay for the
identiﬁcation of seed match sites.
HeLa cells were transfected with
either the M construct and miR-494
or the O construct and miR-221.
Luciferase activity was rescued
when theOvectorwas cotransfected
with miR-221 or miR-222.
Transfection of miR-494 and the M
mutant vector resulted in only slight
restoration, suggesting the site 3 is
not the only effective seed match
site. C, reporter assay for the
identiﬁcation of additional binding
sites. The Mb construct, which
included additional mutated
nucleotides in site 2 (positions
1,760–1,763) and was transfected
together with miR-494, fully rescued
the luciferase activity compared with
that in the sample transfected with
the M construct. These results
indicate that site 2 is another
effective seed match site for miR-
494. D, restoring KIT expression after
miR-494 inhibition in cells with high
miR-494 expression. The N vector
and miR-494 inhibitor were
cotransfected into HeLa, SNU216,
and GIST882 cells. HeLa and
SNU216 cells, which exhibit high
miR-494 expression, exhibited
restored KIT expression after
miR-494 inhibition. N.C. denotes the
negative control transfected with
nontargeting miRNA.
MiR-494 Downregulates KIT
www.aacrjournals.org Clin Cancer Res; 17(24) December 15, 2011 7589
expression is directly regulated by endogenous miR-494
even in cell lines that do not express KIT, such as HeLa and
SNU216 cells. We also carried out a reporter assay to
determine whether the M or Mb vector is affected by
miR-494 inhibition. As expected, whereas the M vector was
affected by both miR-494 overexpression and miR-494
inhibition, the Mb vector was not affected by either condi-
tion. These results confirmed that 2 different binding sites
are important for binding betweenmiR-494 and the KIT 30-
UTR. Both M and Mb vectors were affected by miR-221
overexpression, thus indicating that the constructs worked
properly (Supplementary Fig. S6).
Signaling perturbed after miR-494 treatment
The KIT downstream molecular pathway is known to be
related to cell proliferation, differentiation, and apoptosis.
The regulation of KIT expression affects critical pathways
including AKT, ERK, and JACK-STAT pathways, as suggested
by many studies (6). The effects of miR-494 on those
pathways were shown by analyzing the status of p-AKT,
p-ERK, p-KIT, and p-STAT3 after miR-494 transfection.
GIST882 cells were transfected with 50 nmol/L nontarget-
ing miRNA, miR-494, miR-221, or an miR-494 inhibitor.
TransfectionwithmiR-494 significantly reduced KIT expres-
sion in these cells. Transfection with miR-221 also reduced
KIT expression but to a lesser extent than miR-494 trans-
fection. As expected, miR-494 inhibition did not influence
KIT expression due to the very low endogenous miR-494
expression level in the GIST882 cell line. Expression of
phospho-KIT (pY703) was examined with a phospho-
specific antibody and found to significantly decrease in
cells transfected with miR-494. The active forms of the 3
downstream molecules in KIT signaling pathways, AKT,
ERK, and STAT3, were then analyzed. The expression of
phospho-AKT, as measured by a phospho-AKT–specific
antibody, was decreased by miR-221 and miR-494 over-
expression,with thedownregulationof phospho-AKTbeing
much larger after miR-494 overexpression than after miR-
221 overexpression. The pattern of changes in phospho-
STAT3 expression was similar to that of phospho-AKT
expression after miR-221 and miR-494 overexpression
and the decreases were larger after miR-494 overexpression.
No significant change in phospho-ERK expression was
observed (Fig. 3).
Induced miR-494 overexpression inhibits GIST cell
proliferation
The effect of miR-494 on the proliferation of GIST882
cellswas determinedby a cell proliferation assay.During the
assay, the normalcy of cell morphology was regularly con-
firmed. No remarkable changes occurred after 3 days. How-
ever, the cells transfected with miR-494 had markedly
reduced numbers of cells and cell clusters 6 days after the
first transfection, and these changes becamemore severe on
the 12th day of the assay. Whereas GIST882 cells normally
exhibit a spindle shape with pin-point end structure,
GIST882 cells transfected with miR-494 had altered cell
morphology on the 12thday of the assay (Fig. 4A), and their
cell numbers were reduced to approximately 37% of the
number of control group cells (Fig. 4B). In addition, we
found increased numbers of dead cells floating in the
culture media after miR-494 transfection. Sustained KIT
downregulation was confirmed by Western blotting of the
same samples used in a proliferation assay (Fig. 4C).
We used another cellmodel to verify the biological effects
of miR-494 that is not cell line specific and common to the
other cells with activated KIT. Wild-type KIT is activated by
stem cell factor (SCF), whereas mutant KIT is constantly
activated without SCF (6, 22). We selected DLD-1, which
overexpresses wild-type KIT, to validate the effect of miR-
494 treatment. By using this SCF–KIT signaling model, we
tried to confirm thebiological effects ofmiR-494on the cells
with activated KIT (23). We showed that DLD-1 cell line
overexpresses KIT by RT-PCR and Western blotting
Figure 3. Decreased expression of p-AKT and p-STAT3 in GIST882 cells
transfected with miR-494. Transfection of miR-494 into GIST882 cells
induced signiﬁcant changes in the AKT and STAT signaling pathways.
The expression levels of KIT and phospho-KIT were markedly reduced
after transfecting GIST882 cells with miR-494. The expression of both
phospho-AKT and phospho-STAT3, downstream molecules of KIT
signaling pathways, was decreased. Little difference was found between
control samples and those treated with themiR-494 inhibitor. % denotes
the relative intensity of protein expression. N.C. denotes the negative
control transfected with nontargeting miRNA.
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(Supplementary Fig. S7A). In DLD-1 cell line, the level of p-
AKT and the level of p-ERK were not detectable before SCF
stimulation. SCF stimulation in the DLD-1 cell line induces
large amounts of both p-KIT, p-AKT and a small amount of
p-ERK. On the basis of these results, we firstly showed that
miR-494 transfection reduces the KIT protein expression to
approximately 40%of the expressionof thenegative control
at bothmRNA and protein levels (Supplementary Fig. S7B).
When the DLD-1 cell line stimulated with SCF was treated
with miR-494, the levels of p-KIT, p-AKT, and p-ERK were
markedly decreased (Supplementary Fig. S7C). Also, the
enhanced cellular proliferation of the DLD-1 cell line with
SCF treatment was markedly inhibited after miR-494 treat-
ment (Supplementary Fig. S7D).
Apoptosis and cell-cycle analysis after miR-494
overexpression in GIST882 cells
Changes in the cell-cycle distribution of GIST882 cells
after miR-494 transfection was assessed by flow cytometry.
Cells transfected with miR-494 had a 6% increase in the
number of G0–G1 phase cells and a 5% decrease in the
number of S phase cells compared with cells transfected
with nontargeting miRNA (Fig 5A). These findings indicate
that miR-494 inhibits GIST882 cell proliferation by mod-
ulating the cell cycle. We also examined apoptotic changes
after miR-494 transfection by using a combination of
Annexin V and PI. The result indicated that approximately
25% of cell populations undergo early or late apoptotic
changes after miR-494 transfection (Fig 5B). Reduced KIT
expression was confirmed by Western blotting during the
experiment. These data indicate that miR-494 treatment
induces both cell-cycle arrest and apoptosis in GIST882
cells.
Discussion
miRNAs can posttranscriptionally regulate target genes
and components of target gene regulatory pathways, thus
affecting signal transduction both directly and indirectly.
These findings suggest that miRNAs play major regulatory
roles in signal transduction pathways and tumorigenesis
(15, 16). Mutations of KIT and KIT overexpression are
interrelated with KIT-induced tumorigenesis, and dysregu-
lated miRNA expression might explain KIT overexpression
and the resulting tumorigenesis (12, 13).MiR-221 andmiR-
222 have been reported to negatively regulate erythroleu-
kemic cell growth by targeting KIT (17). However, no
miRNAs involved in GIST tumorigenesis by targeting KIT
have been reported. We herein proposed that miR-494
directly targets KIT by showing that exogenous miR-494
induces KIT downregulation, and miR-494 inhibition
induces KIT overexpression. Downregulation of KIT occurs
more potently in vitrowithmiR-494 thanwithmiR-221 and
miR-222, the previously reported KIT-targeting miRNAs.
Moreover, the expression level ofmiR-221 andmiR-222was
not related to KIT expression in GISTs (13).
Until now, the role of miR-494 in GISTs and other
diseases was poorly understood. No genes had been
reported to be targeted by miR-494, excluding a report that
miR-494 could downregulate PTEN expression in a chem-
ically transformed cell line (24). However, we could not
show significant changes in PTEN expression after miR-494
overexpression in GIST882 cells (Supplementary Fig. S8).
Other studies reported the decreased expression ofmiR-494
in lymphomaand squamous cell carcinomaof the head and
neck in miRNA microarray profiling studies (25, 26); how-
ever, the direct relationship between this decreased expres-
sion and tumor-related gene expression has not been
Figure 4. GIST cell proliferation is inhibitedbymiR-494. A, themorphology
of GIST882 cells is shown 12 days after transfection. GIST882 cells
transfected with miR-494 had sparse cell clusters and irregular cell
morphology on the 12th day. B, the number of GIST882 cells treated with
miR-494.GIST882cells exhibitedmarkedly reducednumbersof cells and
cell clusters 6 days after the ﬁrst transfection, and these changes became
more severe on the12th day of the assay. C,Western blots of the samples
in the proliferation assay revealed that the GIST882 cells transfected
with miR-494 had reduced KIT expression. % denotes the relative
intensity of protein expression. N.C. denotes the negative control
transfected with nontargeting miRNA.
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reported. In addition to the inverse expression between KIT
andmiR-494 expression in GISTs, we showed that miR-494
directly downregulates KIT by binding 2 different seed
match sites. We also showed miR-494 inhibition induces
KIT overexpression. Therefore, we conclude that miR-494 is
a major miRNA that regulates KIT in GISTs.
The protein KIT is a highly oncogeneic tyrosine kinase
that belongs to the RTK family and is involved in the major
signal transduction pathways of PI3 kinase-AKT, Src family
kinase, and Ras-ERK and in the minor signal transduction
pathway of JAK-STAT. Wild-type KIT is activated by SCF,
whereas mutant KIT is constantly activated without SCF
(6, 22, 23). Mutations of the transmembrane domain
constantly activate KIT receptor dimerization, leading to
the activation of downstream signaling (27). Gain-of-func-
tion mutations are frequently found in exons 9, 11, 13, and
17 of the KIT gene and contribute to GIST tumorigenesis
(3, 28). This study showed that the downregulation of
mutant KIT induced by miR-494 affects the expression of
p-AKT and p-STAT3. These findings are consistent with
previous reports indicating that p-AKT and p-STAT3 expres-
sion were decreased after GIST882 cells with activated KIT
were treated with imatinib or KIT short hairpin RNA.
Moreover, we also showed that the induced p-AKT and p-
ERK by SCF stimulation in the wild-type KIT overexpressing
cells are specifically decreased after miR-494 transfection.
Imatinib inhibits KIT through its ATP-binding pocket,
affecting KIT phosphorylation and subsequently inactivat-
ing downstreammolecules (29–32).Our study showed that
miR-494 transfection has similar effects on GIST882 cells as
imatinib, such as perturbing signaling pathways and sup-
pressing cell proliferation. These findings indicate thatmiR-
494 overexpression could be another alternative treatment
option for GISTs. Our identification of 2 different seed
match sites for miR-494 in the 30-UTR of KIT further sup-
ports the concept of KIT mRNA as the direct target of miR-
494 and creates more practical therapeutic possibilities for
GISTs with KIT activation.
Oncoproteins can be inhibited posttranslationally or
posttransciptionally (33). The inhibition of KIT by imatinib
is an example of posttranslational inhibition through com-
petitively binding the ATP-binding pocket of KIT. However,
KIT inhibition by imatinib is imperfect because resistance
can occur through putative mutations that can develop in
Figure 5. Analysis of apoptosis and cell-cycle distribution after miR-494 transfection. A, cell-cycle analysis after miR-494 transfection. GIST882 cells
transfected with nontargeting miRNA (left) or miR-494 (right) were harvested on day 4 and stained with PI. miR-494 transfection resulted in a 5.6%
increase in the number of G0–G1phase cells and a 5.7%decrease in the number of S phase cells relative to the cell numbers for cells treatedwith nontargeting
miRNA. B, apoptosis analysis after miR-494 transfection. Six days after transfection with or without miR-494, GIST882 cells were stained with PI and Annexin
V. Approximately 25% of GIST882 cells treated with miR-494 undergo apoptosis. % denotes the relative intensity of protein expression. N.C.
denotes the negative control transfected with nontargeting miRNA.
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the specific amino acid sequences during treatment. The
resultant imatinib resistance occurs through the inhibition
of imatinib binding to the ATP-binding pocket of KIT (11).
More therapeuticoptionsareneededfor resistancecausedby
these mutations. The therapeutic use of miR-494 to inacti-
vate KIT will continue to be challenging because traditional
RNA-based therapies are instable in blood and siRNAs have
paradoxically largemolecular sizes.However,manyof these
problems are being solved by new delivery systems such as
aptamers, nanoparticles, and liposomes (34–36). Applying
thesenewdelivery systemswill allowmiR-494 tobeusedasa
novel therapeutic tool to treat GISTs.
In conclusion, miR-494 is a potent regulator of KIT in
GISTs, and introducing miR-494 into GISTs may be a novel
mechanism of reversing tumor progression.
Disclosure of Potential Conﬂicts of Interest
No potential conflicts of interest were disclosed.
Grant Support
This research was funded by grant number FPR08A2-100 sponsored by
the 21C Frontier Functional Proteomics Project, Korean Ministry of Educa-
tion, Science, and Technology and by the Converging Research Center
Program through the Ministry of Education, Science and Technology
(2010K001115).
The costs of publication of this article were defrayed in part by the
payment of page charges. This article must therefore be hereby marked
advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate
this fact.
Received January 19, 2011; revised September 23, 2011; accepted October
20, 2011; published OnlineFirst October 31, 2011.
References
1. Fletcher CD, Berman JJ, Corless C, Gorstein F, Lasota J, Longley BJ,
et al. Diagnosis of gastrointestinal stromal tumors: A consensus
approach. Hum Pathol 2002;33:459–65.
2. Miettinen M, Lasota J. Gastrointestinal stromal tumors–deﬁnition,
clinical, histological, immunohistochemical, and molecular genetic
features and differential diagnosis. Virchows Arch 2001;438:1–12.
3. Miettinen M, Lasota J. Gastrointestinal stromal tumors: review on
morphology, molecular pathology, prognosis, and differential diagno-
sis. Arch Pathol Lab Med 2006;130:1466–78.
4. Duensing A, Medeiros F, McConarty B, Joseph NE, Panigrahy D,
Singer S, et al. Mechanisms of oncogenic KIT signal transduction in
primary gastrointestinal stromal tumors (GISTs). Oncogene 2004;23:
3999–4006.
5. HeinrichMC, Corless CL, Duensing A,McGreevey L, Chen CJ, Joseph
N, et al. PDGFRA activating mutations in gastrointestinal stromal
tumors. Science 2003;299:708–10.
6. Lennartsson J, Ronnstrand L. The stem cell factor receptor/c-Kit as a
drug target in cancer. Curr Cancer Drug Targets 2006;6:65–75.
7. Tuveson DA, Willis NA, Jacks T, Grifﬁn JD, Singer S, Fletcher CD,
et al. STI571 inactivation of the gastrointestinal stromal tumor c-KIT
oncoprotein: biological and clinical implications. Oncogene 2001;
20:5054–8.
8. Gordon PM, Fisher DE. Role for the proapoptotic factor BIM in
mediating imatinib-induced apoptosis in a c-KIT-dependent gastro-
intestinal stromal tumor cell line. J Biol Chem;285:14109–14.
9. Bauer S, Duensing A, Demetri GD, Fletcher JA. KIT oncogenic sig-
naling mechanisms in imatinib-resistant gastrointestinal stromal
tumor: PI3-kinase/AKT is a crucial survival pathway. Oncogene
2007;26:7560–8.
10. Ma Y, Zeng S, Metcalfe DD, Akin C, Dimitrijevic S, Butterﬁeld JH,
et al. The c-KIT mutation causing human mastocytosis is resistant
to STI571 and other KIT kinase inhibitors; kinases with enzymatic
site mutations show different inhibitor sensitivity proﬁles than wild-
type kinases and those with regulatory-type mutations. Blood 2002;
99:1741–4.
11. McLean SR, Gana-Weisz M, Hartzoulakis B, Frow R, Whelan J, Sel-
wood D, et al. Imatinib binding and cKIT inhibition is abrogated by the
cKIT kinase domain I missense mutation Val654Ala. Mol Cancer Ther
2005;4:2008–15.
12. Kang HJ, Nam SW, Kim H, Rhee H, Kim NG, Hyung WJ, et al.
Correlation of KIT and platelet-derived growth factor receptor alpha
mutations with gene activation and expression proﬁles in gastrointes-
tinal stromal tumors. Oncogene 2005;24:1066–74.
13. Choi HJ, Lee H, Kim H, Kwon JE, Kang HJ, You KT, et al. MicroRNA
expression proﬁle of gastrointestinal stromal tumors is distinguished
by 14q loss and anatomic site. Int J Cancer;126:1640–50.
14. Quek R, George S. Gastrointestinal stromal tumor: a clinical overview.
Hematol Oncol Clin North Am 2009;23:69–78, viii.
15. Schickel R, Boyerinas B, Park SM, Peter ME. MicroRNAs: key players
in the immune system, differentiation, tumorigenesis and cell death.
Oncogene 2008;27:5959–74.
16. Calin GA, Croce CM.MicroRNA signatures in human cancers. Nat Rev
Cancer 2006;6:857–66.
17. Felli N, Fontana L, Pelosi E, Botta R, Bonci D, Facchiano F, et al.
MicroRNAs 221 and 222 inhibit normal erythropoiesis and erythroleu-
kemic cell growth via kit receptor down-modulation. Proc Natl Acad
Sci U S A 2005;102:18081–6.
18. KangHJ, Koh KH, Yang E, You KT, KimHJ, Paik YK, et al. Differentially
expressed proteins in gastrointestinal stromal tumors with KIT and
PDGFRA mutations. Proteomics 2006;6:1151–7.
19. Kim NG, Kim JJ, Ahn JY, Seong CM, Noh SH, Kim CB, et al. Putative
chromosomal deletions on 9P, 9Q and 22Q occur preferentially in
malignant gastrointestinal stromal tumors. Int J Cancer 2000;85:
633–8.
20. Agaimy A. Gastrointestinal stromal tumors (GIST) from risk stratiﬁca-
tion systems to the new TNMproposal: more questions than answers?
A review emphasizing the need for a standardizedGIST reporting. Int J
Clin Exp Pathol 2010;3:461–71.
21. Livak KJ, Schmittgen TD. Analysis of relative gene expression data
using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.
Methods 2001;25:402–8.
22. Bellone G, Carbone A, Sibona N, Bosco O, Tibaudi D, Smirne C, et al.
Aberrant activation of c-kit protects colon carcinoma cells against
apoptosis and enhances their invasive potential. Cancer Res 2001;61:
2200–6.
23. YasudaA, Sawai H, Takahashi H, Ochi N,MatsuoY, Funahashi H, et al.
Stem cell factor/c-kit receptor signaling enhances the proliferation and
invasion of colorectal cancer cells through the PI3K/Akt pathway. Dig
Dis Sci 2007;52:2292–300.
24. Liu L, Jiang Y, Zhang H, Greenlee AR, Han Z. Overexpressed miR-494
down-regulates PTEN gene expression in cells transformed by anti-
benzo(a)pyrene-trans-7,8-dihydrodiol-9,10-epoxide. Life Sci 2010;86:
192–8.
25. Chang SS, Jiang WW, Smith I, Poeta LM, Begum S, Glazer C, et al.
MicroRNA alterations in head and neck squamous cell carcinoma. Int J
Cancer 2008;123:2791–7.
26. Robertus JL, Kluiver J,WeggemansC,HarmsG,ReijmersRM, Swart Y
, et al. MiRNA proﬁling in B non-Hodgkin lymphoma: a MYC-related
miRNA proﬁle characterizes Burkitt lymphoma. Br J Haematol 2010;
149:896–9.
27. Lux ML, Rubin BP, Biase TL, Chen CJ, Maclure T, Demetri G, et al. KIT
extracellular and kinase domain mutations in gastrointestinal stromal
tumors. Am J Pathol 2000;156:791–5.
28. Nakahara M, Isozaki K, Hirota S, Miyagawa J, Hase-Sawada N,
Taniguchi M, et al. A novel gain-of-function mutation of c-kit gene in
gastrointestinal stromal tumors. Gastroenterology 1998;115:1090–5.
MiR-494 Downregulates KIT
www.aacrjournals.org Clin Cancer Res; 17(24) December 15, 2011 7593
29. Demetri GD. Structural reengineering of imatinib to decrease cardiac
risk in cancer therapy. J Clin Invest 2007;117:3650–3.
30. Heinrich MC, Grifﬁth DJ, Druker BJ, Wait CL, Ott KA, Zigler AJ.
Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a
selective tyrosine kinase inhibitor. Blood 2000;96:925–32.
31. Joensuu H, Roberts PJ, Sarlomo-Rikala M, Andersson LC, Tervahar-
tiala P, Tuveson D, et al. Effect of the tyrosine kinase inhibitor STI571 in
apatientwith ametastatic gastrointestinal stromal tumor.NEngl JMed
2001;344:1052–6.
32. OuWB, Zhu MJ, Demetri GD, Fletcher CD, Fletcher JA. Protein kinase
C-theta regulates KIT expression and proliferation in gastrointestinal
stromal tumors. Oncogene 2008;27:5624–34.
33. Yang Y, Zhou F, Fang Z,Wang L, Li Z, Sun L, et al. Post-transcriptional
and post-translational regulation of PTEN by transforming growth
factor-beta1. J Cell Biochem 2009;106:1102–12.
34. Semple SC, Akinc A, Chen J, Sandhu AP, Mui BL, Cho CK, et al.
Rational design of cationic lipids for siRNA delivery. Nat Biotechnol
2010;28:172–6.
35. Pastor F, Kolonias D, Giangrande PH, Gilboa E. Induction of tumour
immunity by targeted inhibition of nonsense-mediated mRNA decay.
Nature 2010;465:227–30.
36. WangT, LiM,GaoH,WuY.Nanoparticle carriers basedoncopolymers
of poly(epsilon-caprolactone) and hyperbranched polymers for drug
delivery. J Colloid Interface Sci 2011;353:107–15.
Kim et al.
Clin Cancer Res; 17(24) December 15, 2011 Clinical Cancer Research7594
